A
Alexey S. Revenko
Researcher at Isis Pharmaceuticals
Publications - 75
Citations - 4119
Alexey S. Revenko is an academic researcher from Isis Pharmaceuticals. The author has contributed to research in topics: Cancer & Gene knockdown. The author has an hindex of 25, co-authored 65 publications receiving 3363 citations. Previous affiliations of Alexey S. Revenko include Russian Academy of Sciences & University of California, Davis.
Papers
More filters
Journal ArticleDOI
The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
Tony Gutschner,Monika Hämmerle,Moritz Eißmann,Jeff Hsu,Youngsoo Kim,Gene Hung,Alexey S. Revenko,Gayatri Arun,Marion Stentrup,Matthias Groß,Martin Zörnig,A. Robert MacLeod,David L. Spector,Sven Diederichs +13 more
TL;DR: A loss-of-function model unravels the active function of MALAT1 as a regulator of gene expression governing hallmarks of lung cancer metastasis with this ncRNA serving as both predictive marker and therapeutic target.
Journal ArticleDOI
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
David S. Hong,Razelle Kurzrock,Youngsoo Kim,Richard Woessner,Anas Younes,John Nemunaitis,Nathan Fowler,Tianyuan Zhou,Joanna Schmidt,Minji Jo,Samantha J. Lee,Mason Yamashita,Steven G. Hughes,Luis Fayad,Sarina Anne Piha-Paul,Murali V P Nadella,Morvarid Mohseni,Deborah Lawson,Corinne Reimer,David C. Blakey,Xiaokun Xiao,Jeff Hsu,Alexey S. Revenko,Brett P. Monia,A. Robert MacLeod +24 more
TL;DR: High-affinity next-generation antisense oligonucleotides are used, which have higher potency than previous generations and can be systemically administered without a lipid vehicle, for targeting the gene encoding the transcription factor STAT3, a notoriously difficult protein to inhibit therapeutically.
Journal ArticleDOI
Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding
Alexey S. Revenko,Dacao Gao,Jeff Crosby,Gourab Bhattacharjee,Chenguang Zhao,Chris May,David Gailani,Brett P. Monia,A. Robert MacLeod +8 more
TL;DR: The results support the concept that fXII and PKK play important and perhaps nonredundant roles in pathogenic thrombus propagation, and highlight a novel, specific and safe pharmaceutical approach to target these contact system proteases.
Journal ArticleDOI
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk
Hong Zhang,Ester C. Löwenberg,Jeffrey R. Crosby,A. Robert MacLeod,Chenguang Zhao,Dacao Gao,Chris Black,Alexey S. Revenko,Joost C. M. Meijers,Erik S.G. Stroes,Marcel Levi,Brett P. Monia +11 more
TL;DR: The concept that inhibition of FXI through antisense therapy might serve as a new and effective strategy for the treatment and prevention of venous thromboembolism with improved specificity and safety is supported.
Journal ArticleDOI
ANCCA/ATAD2 Overexpression Identifies Breast Cancer Patients with Poor Prognosis, Acting to Drive Proliferation and Survival of Triple-Negative Cells through Control of B-Myb and EZH2
Ekaterina V. Kalashnikova,Alexey S. Revenko,Abigael T. Gemo,Nicholas P Andrews,Clifford G. Tepper,June X. Zou,Robert D. Cardiff,Alexander D. Borowsky,Hongwu Chen +8 more
TL;DR: The results suggest that ANCCA may integrate multiple oncogenic programs in breast cancer, serving in particular as a prognostic marker and a therapeutic target for triple-negative cancers.